XML 69 R57.htm IDEA: XBRL DOCUMENT v3.19.1
Pro Forma Financial Statements (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
May 06, 2016
Dec. 29, 2015
Jul. 24, 2017
Feb. 28, 2017
Aug. 26, 2016
Mar. 31, 2016
Dec. 31, 2018
Dec. 31, 2017
Pro Forma Adjustments (Textual)                
Common stock newly issued, value             $ 80,000 $ 5,850,000
Fully expense entire amount             10,000,000  
Aggregate amount             $ 10,000,000  
Common stock, par value             $ 0.001 $ 0.001
ABVC [Member]                
Pro Forma Adjustments (Textual)                
Due from related parties             $ 59,810  
Due to related parties             $ 58,684  
Common stock newly issued, shares             29,561,231  
Closing share price             $ 1.50  
BioLite, Inc., [Member]                
Pro Forma Adjustments (Textual)                
Common stock newly issued, value         $ 1,468,750      
Net proceeds from offering         $ 2,350,000      
Common stock, par value         $ 0.001      
Purchase price per share         $ 1.60      
Collaborative Arrangement [Member]                
Pro Forma Adjustments (Textual)                
Amount received from BriVision   $ 100,000,000 $ 3,000,000          
Description of payment settlement   Upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. Upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. Upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. At the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. Upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.            
Agreement, terms   This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.            
Upfront payments   $ 3,500,000            
Percentage of payments under collaborative agreement   3.50% 50.00%       15.00%  
Milestone payments to BioLite in cash $ 2,600,000              
Common stock newly issued, value $ 900,000   $ 3,000,000          
Common stock newly issued, shares 562,500              
Share price $ 1.60     $ 2.0        
Accounts payable             $ 15,000,000  
Collaborative Arrangement One [Member]                
Pro Forma Adjustments (Textual)                
Percentage of payments under collaborative agreement           6.50%    
Milestone payments to BioLite in cash       $ 650,000        
Common stock newly issued, value       $ 5,850,000        
Common stock newly issued, shares       2,925,000        
Share price       $ 2.0        
Accounts payable           $ 6,500,000    
BioLite Collaborative Agreement [Member]                
Pro Forma Adjustments (Textual)                
Common stock newly issued, value             $ 6,750,000  
Common stock newly issued, shares             3,487,500  
Investment loss recognized write-off amount             $ 4,313,725